Submission of Notice of Extra Ordinary General Meeting.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Astal Laboratories has called an EGM on 6 November 2025 (via video conferencing) with three key items. First, it seeks shareholder approval to increase the authorised share capital from Rs. 20 crore to Rs. 50 crore (from 2 crore to 5 crore equity shares of Rs. 10 each). Second, it wants approval to acquire 100% of Sriven Pharmachem India Private Limited (SPIPL) through a share swap, issuing up to 3,04,58,187 new shares at Rs. 91 per share (including Rs. 81 premium), aggregating to about Rs. 277.17 crore, to the 135 existing SPIPL shareholders. Third, it seeks approval for a related-party transaction: the acquisition of 0.82% stake in SPIPL from Mr. Sudheer Karna Kankanala (Whole-time Director), involving 2.5 lakh shares of Astal valued at about Rs. 2.275 crore. The relevant date for pricing is 7 October 2025 and Acuite Ratings has been appointed as monitoring agency for the deal.
If approved, existing Astal shareholders will face significant dilution as 3.04 crore new shares will be issued (a substantial increase over the current 2 crore authorised share base). The acquisition expands Astal's pharma business through SPIPL, but the price of Rs. 91 per share is well above face value of Rs. 10, so the deal is priced at a significant premium. Shareholders should note the related-party component and review the swap ratio before voting.